

**POLICY:** Dermatology – Ycanth Utilization Management Medical Policy

- Ycanth™ (cantharidin 0.7% topical solution – Verrica)

**EFFECTIVE DATE:** 07/01/2024

**REVIEW DATE:** 09/16/2024

**COVERAGE CRITERIA FOR:** All Aspirus Medicare Plans

---

### **OVERVIEW**

Ycanth, a cantharidin-based topical solution, is indicated for the treatment of molluscum contagiosum in patients 2 years of age and older.<sup>1</sup>

### **Disease Overview**

Molluscum contagiosum is a viral skin infection of the Poxviridae family that can cause white, pink, or flesh colored bumps either alone, or in groups; it is spread by direct contact.<sup>2,3</sup> Common locations are the trunk, face, and extremities. Patients may experience pain, itching, and eczema, as well as secondary bacterial infections. Resolution usually occurs within 6 to 12 months; in selected cases it can take longer for the skin infection to completely disappear. The condition is found in children and adults; however, it is more common in younger patients. Immunocompetent patients can often clear the infection without treatment. However, patients with additional dermatologic conditions (e.g., atopic dermatitis), or in those who are immunocompromised, have more extensive infection that is harder to treat. Molluscum contagiosum is most common in warm, humid climates.

### **Clinical Efficacy**

The efficacy of Ycanth for the treatment of molluscum contagiosum infections has been evaluated in two pivotal studies.<sup>1,4</sup> The studies included patients  $\geq 2$  years of age with a clinical diagnosis of molluscum contagiosum with treatable lesions. The primary efficacy endpoint was the proportion of the Ycanth treated patients achieving complete clearance of all molluscum contagiosum lesions compared to those who received the vehicle at Day 84 of trial.

### **Guidelines**

Ycanth is not addressed in guidelines. The American Academy of Pediatrics (AAP) RedBook 2021-2024 cite that cryotherapy, curettage and cantharidin (compounded) have the most support for treatment.<sup>2</sup>

### **POLICY STATEMENT**

Prior Authorization is recommended for medical benefit coverage of Ycanth. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days.

**Automation:** None.

### **RECOMMENDED AUTHORIZATION CRITERIA**

Coverage of Ycanth is recommended in those who meet the following criteria:

#### **FDA-Approved Indication**

- 1. Molluscum Contagiosum.** Approve Ycanth for 3 months if the patient meets ALL of the following (A, B, and C):
  - A)** Patient is  $\geq 2$  years of age; AND
  - B)** Approve if patient meets ONE of the following (i or ii):
    - i.** Patient is treating new lesions that have not previously been treated with Ycanth;  
OR
    - ii.** Patient is treating lesions that have been previously treated with Ycanth for less than 4 treatment cycles; AND
  - C)** Ycanth is being administered by a healthcare professional.

**Dosing.** Approve two applicators per treatment, once every 21 days.

---

### **CONDITIONS NOT RECOMMENDED FOR APPROVAL**

Coverage of Ycanth is not recommended in the following situations:

- 1.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### **REFERENCES**

1. Ycanth™ topical solution [prescribing information]. West Chester, PA: Verrica; July 2023.
2. American Academy of Pediatrics. Red Book: 2021-2024 report of the Committee of Infectious Diseases (32<sup>nd</sup> Edition). Molluscum Contagiosum. Pages 535-537.

3. Badri T, Gandhi GR. Molluscum Contagiosum. [Updated March 27, 2023]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK441898/>. Accessed on February 12, 2024.
4. Eichenfield LF, McFalda W, Barbec B, et al. Safety and Efficacy of VP-102, a proprietary, drug-device combination product containing cantharidin, 0.7% (w/v), in children and adults with molluscum contagiosum: two phase 3 randomized clinical trials. *JAMA Dermatol.* 2020;156(12):1315-1323.

**HISTORY**

<b>Type of Revision</b>	<b>Summary of Changes</b>	<b>Review Date</b>
New Policy		02/28/2024
Aspirus P&T Review	Policy reviewed and approved by Aspirus P&T committee. Annual review process	09/16/2024